<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332005</url>
  </required_header>
  <id_info>
    <org_study_id>NM-ARI-231</org_study_id>
    <nct_id>NCT02332005</nct_id>
  </id_info>
  <brief_title>12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study</brief_title>
  <acronym>DE-DPN</acronym>
  <official_title>Twelve-Month Chronic Efficacy and Safety of Diepalrestat in Adult Subjects With Diabetic Peripheral Neuropathy (DPN), A Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuromaxBionevia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuromaxBionevia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An interventional study to investigate the efficacy and safety of diepalrestat (BNV-222) in
      diabetic patients with diabetic peripheral neuropathy. Subjects will receive twice daily an
      oral dose of diepalrestat, an aldose reductase inhibitor, or placebo to investigate the
      effect on motor nerve conduction velocity (MNCV) and symptomatic clinical responses over 12
      months of treatment. Subjects will be assessed at screening and baseline, with office visits
      every 12 weeks, for a total of 6 visits. The study will explore in a double-blind fashion,
      the effect of two doses of diepalrestat, 150 and 300 mg, to reduce the loss in nerve
      conduction velocity that is expected to be demonstrated in the group randomized to placebo
      treatment for up to 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 12 month double-blind, randomized, placebo-controlled, parallel group efficacy and
      safety study will enroll 400 adult diabetic subjects with diabetic peripheral neuropathy
      (DPN) to investigate the effect of diepalrestat (BNV-222) 150 mg, 300 mg, or placebo on MNCV
      and patients' perception of nerve function over 12 months as measured by VAS scales and
      composite clinical outcome patient reported scales that evaluate numbness, tingling,
      cramping, paresthesiae, hyperesthesia, coldness, weakness and spontaneous pain perception of
      upper and lower extremities, and the effects on other measures of nerve motor and sensory
      conduction. Subjects will be assessed at screening and baseline, with office visits every 12
      weeks, for a total of 6 visits. Subjects will be assessed by testing motor nerve conduction
      velocity and other assessments at each office visit. A subgroup of 24 patients will be
      selected for pharmacokinetic (PK) testing for up to 48 hours with additional blood draws on
      Day 7 and 14. This study will investigate the ability of diepalrestat to reduce the ongoing
      deterioration of nerve function which is a hallmark of the DPN process.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in peroneal motor nerve conduction velocity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in patient-reported Visual Acuity Scales</measure>
    <time_frame>12 months</time_frame>
    <description>Patients' perception of pain, numbness, tingling, weakness of the foot, ataxia, upper limb symptoms and sensory symptoms assessed by pinprick, light touch, vibration, and temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in patient-reported responses to Toronto Clinical Neuropathy Score (TCNS)</measure>
    <time_frame>12 months</time_frame>
    <description>TCNS component measures of symptomatic changes in pain, numbness and other measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in quality of life administered by SF-36 instrument</measure>
    <time_frame>12 months</time_frame>
    <description>patient global impression of quality of life assessed by the SF-36 short form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in median conduction velocity measurements</measure>
    <time_frame>12 months</time_frame>
    <description>conduction velocity measures including median MNCV,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in visual acuity compared to baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Change in visual acuity over 12 months compared to baseline, change in diabetic retinopathy in the dilated eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in MFWL conduction velocity measurement</measure>
    <time_frame>12 months</time_frame>
    <description>change from baseline in median F wave latency (MFWL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in VPT conduction velocity measurement</measure>
    <time_frame>12 months</time_frame>
    <description>change from baseline in Vibration Perception Threshold (VPT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Group 1 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet administered twice daily morning and evening containing placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diepalrestat choline</intervention_name>
    <description>aldose reductase inhibitor</description>
    <arm_group_label>Group 1 150 mg</arm_group_label>
    <arm_group_label>Group 2 300 mg</arm_group_label>
    <other_name>BNV-222</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 1 or type 2 diabetes mellitus that is controlled by oral or
             parenteral hypoglycemic agents or diet.

          -  Patients with diabetes that is stable and controlled (HbA1C â‰¤ than 10 %) with no new
             symptoms associated with diabetes within previous 3 months.

          -  Patients diagnosed with neuropathy who have abnormalities in 2 of 3 categories (signs,
             symptoms, and objective tests of nerve conduction studies or quantitative sensory
             threshold testing).

          -  Patients on pain medication (prescribed analgesics), stable for at least 3 months
             before study entry or pain treatment naive.

          -  Patients with at least mild painful symptoms of diabetic neuropathy for at least 1
             year duration, but not longer than 10 years duration.

          -  Able to withstand the fundus evaluation during ophthalmology testing

        Exclusion Criteria:

          -  A condition that would preclude a patient for participation in the study in opinion of
             investigator, e.g., unstable medical status including glycemic control and blood
             pressure.

          -  Any neurological disorder that may confound assessment of diabetic peripheral
             neuropathy such as radiculopathies. multiple sclerosis, myelopathies.

          -  Ongoing severe peripheral arterial diseases, skin ulcers, or amputation in the lower
             extremities.

          -  Neuropathy findings due to any of the following: alcohol abuse, liver or renal
             disease, toxic exposure, endocrine, metabolic or nutritional disorders, inflammatory
             diseases, or monoclonal gammopathies.

          -  Patients with absent peroneal nerve response.

          -  Other pain that may confound assessment of neuropathic pain.

          -  Previous participation in any studies of investigational drugs within 1 month
             preceding Day 0 (excluding vitamins and minerals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Mockot, MD</last_name>
    <role>Study Director</role>
    <affiliation>NeuroMax Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Caron, PhD</last_name>
    <phone>(617) 640-5043</phone>
    <email>judy.caron@bionevia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexey Eliseev, PhD</last_name>
    <phone>(617) 519-3728</phone>
    <email>aeliseev@maxwellbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City Hospital No 40 of the Kurortny District</name>
      <address>
        <city>St Petersburg</city>
        <state>Sestroretsk</state>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S A Agafina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern State Medical University</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A T Zykova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Services Severstal</name>
      <address>
        <city>Cherepovets</city>
        <zip>162600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V A Simonov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A V Shirokov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kemerovo Regional Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V L Kvitkova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology Dispensary</name>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M B Antsiferov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morozovskaya Children City Hospital of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Petryaykina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>I M Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I A Strokov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IM Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V A Zilov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IM Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A N Petunina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No 71</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A S Berns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital No 1 of JSC Russian Railway</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A W Volchik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No 50</name>
      <address>
        <city>Moscow</city>
        <zip>127206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L A Vertkin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Federal Bureau of Medical and Social Expertise</name>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V I Guryeva, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Perm State Medical Academy</name>
      <address>
        <city>Perm</city>
        <zip>614107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V Y Karakulova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Baranov Respublical Hospital</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N N Vezikova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A V Balyazin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Polyclinic No 20</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V O Reshetko, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imc Sogaz</name>
      <address>
        <city>St Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O A Amelina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Reavita</name>
      <address>
        <city>St Petersburg</city>
        <zip>194295</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B V Popova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital of the Holy Martyr Elizabeth</name>
      <address>
        <city>St Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V N Vorokhobina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nikolaev Hospital</name>
      <address>
        <city>St Petersburg</city>
        <zip>198510</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Y Malikov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bashkir State Medical University</name>
      <address>
        <city>Ufa</city>
        <zip>450000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O L Andrianova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central City Clinical Hospital</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A M Shutov, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Medical University</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V O Magnitskakya, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V V Marasaev, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NV Solovyov Clinical Emergency Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>V V Yakusevich, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2015</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

